对肺动脉高血压的新见解:PANoptosis和周围血管炎症反应之间的相互作用
Xianli Su1,2, Yinhui Sun2,3, Aiguo Dai4,5,6
1College of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
Apoptosis : an international journal on programmed cell death
|February 20, 2025
概括
肺动脉高血压 (PAH) 涉及由细胞死亡和炎症驱动的血管重塑. 这篇评论探讨了PANoptosis,即同时发生的细胞死亡过程,以及它与PAH炎症的联系,表明了治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 肺动脉高血压 (PAH) 的特点是肺血管重塑.
- 在PAH中血管重塑与异常细胞死亡和炎症有关.
- PANoptosis,即同时编程的细胞死亡,是一种新发现的现象.
研究的目的:
- 审查PAH中亡,亡,烧亡和炎症的机制.
- 专注于PANoptosis与PAH炎症的作用和相互作用.
- 阐明PANoptosis和炎症在PAH病理生理学中的意义,并探索治疗点.
主要方法:
- 对编程细胞死亡 (PCD) 和PAH炎症现有文献的审查.
- 分析不同PCD途径 (亡,亡,烧亡) 和炎症之间的相互作用.
- 在PAH的背景下检查PANoptosis的新兴概念.
主要成果:
- 同时激活各种细胞死亡形式,促进免疫细胞的粘附和炎症.
- 炎症可以触发细胞死亡,共同加速PAH中的血管重塑.
- 泛性亡代表了PAH中细胞死亡和炎症的复杂相互作用.
结论:
- 帕诺普托斯及其与炎症的相互作用在PAH病变发生过程中至关重要.
- 了解PANoptosis为PAH机制提供了新的见解.
- 向PANoptosis和相关炎症可能为PAH提供新的治疗策略.
关键词:
细胞灭亡 (apoptosis) 是一种死亡的过程.炎症 炎症是一种炎症.尸体灭 (Necroptosis) 是一种死亡的过程.这就是PANoptosis.肺动脉高血压是什么意思热性灭症 (Pyroptosis) 是一种更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
160
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
160
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K


